Sparks Teresa N, Norton Mary E, Flessel Monica, Goldman Sara, Currier Robert J
Division of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, and the Division of Medical Genetics, Department of Pediatrics, University of California, San Francisco, San Francisco, and the Genetic Disease Screening Program, California Department of Public Health, Richmond, California.
Obstet Gynecol. 2016 Nov;128(5):1127-1133. doi: 10.1097/AOG.0000000000001690.
To evaluate the observed incidence of Down syndrome in twins compared with that expected based on maternal age-matched singletons, which is the current clinical approach.
This was a retrospective review of California Prenatal Screening Program participants with expected delivery dates between July 1995 and December 2012. Cases confirmed prenatally or postnatally with a genetic imbalance leading to phenotypic Down syndrome (trisomy 21, mosaic trisomy 21, or translocations) were included. Pregnancies conceived with ovum donation and women older than 45 years were excluded. We compared the observed Down syndrome incidence per pregnancy for twins with expected incidence by extrapolating from singleton data and expected zygosity as is the current clinical approach. This extrapolation assumes that monozygotic pregnancies have equivalent Down syndrome risk per pregnancy relative to maternal age-matched singletons and dizygotic pregnancies have twice the risk of at least one affected fetus. Zygosity for affected cases was presumed to be monozygotic with Down syndrome concordance and dizygotic with Down syndrome discordance. Counts were compared using cumulative Poisson distributions.
Of 77,279 twin pregnancies, 182 (0.2%) had at least one fetus with Down syndrome confirmed by karyotype. The ratio of observed-to-expected Down syndrome incidence per pregnancy was 33.6%, 75.2%, and 70.0% for monozygotic, dizygotic, and all twins, respectively (P<.001 for all comparisons). Considering maternal age subgroups and twin zygosity, a significantly lower-than-expected Down syndrome incidence was seen for women aged 25 to 45 years with monozygotic pregnancies and overall for women aged 25 to 45 years with dizygotic pregnancies.
The observed incidence of Down syndrome in twin pregnancies is lower than expected, most notably for monozygotic pregnancies and with increasing maternal age. Risk-based counseling can strongly affect women's choices regarding testing and management during pregnancy, so an understanding of the true Down syndrome risk in twin gestations is crucial.
与基于母亲年龄匹配的单胎妊娠预期发病率相比,评估观察到的双胎妊娠中唐氏综合征的发病率,这是当前的临床方法。
这是一项对1995年7月至2012年12月预期分娩日期的加利福尼亚产前筛查项目参与者的回顾性研究。纳入产前或产后确诊为因基因失衡导致表型唐氏综合征(21三体、21号染色体嵌合三体或易位)的病例。排除卵子捐赠受孕的妊娠和45岁以上的女性。我们按照当前临床方法,通过从单胎数据外推并结合预期合子性,比较观察到的双胎妊娠每次妊娠的唐氏综合征发病率与预期发病率。这种外推假设单卵双胎妊娠相对于母亲年龄匹配的单胎妊娠每次妊娠的唐氏综合征风险相同,而异卵双胎妊娠至少有一个受影响胎儿的风险是其两倍。对于受影响病例,若唐氏综合征一致则假定为单卵双胎,若唐氏综合征不一致则假定为异卵双胎。使用累积泊松分布比较计数。
在77279例双胎妊娠中,182例(0.2%)至少有一个胎儿经核型分析确诊为唐氏综合征。单卵双胎、异卵双胎和所有双胎每次妊娠观察到的与预期的唐氏综合征发病率之比分别为33.6%、75.2%和70.0%(所有比较P<0.001)。考虑母亲年龄亚组和双胎合子性,25至45岁单卵双胎妊娠女性以及25至45岁异卵双胎妊娠女性总体的唐氏综合征发病率均显著低于预期。
双胎妊娠中观察到的唐氏综合征发病率低于预期,最明显的是单卵双胎妊娠以及随着母亲年龄增加。基于风险的咨询会强烈影响女性在孕期关于检测和管理的选择,因此了解双胎妊娠中真正的唐氏综合征风险至关重要。